Skip to main content
SpringerLink
Log in

Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey

  • Original Paper
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Human p-glycoprotein encoded by human multidrug resistance (MDR1) gene, is a transmembrane protein that serves as efflux pump for a wide variety of lipophilic compounds possessing a physiological role in protecting cells against the DNA damaging of certain xenobiotics. According to the published data, the frequency of C3435T polymorphism differs depending on the different ethnical populations such as Asian, African, and Caucasians populations. In our study, we identified the MDR1 C3435T polymorphism in 150 healthy volunteers in Denizli province of Turkey. DNA was extracted from peripheral blood samples by standard phenol/chloroform extraction method. Polymerase chain reaction–restriction fragment length polymorphism was used for the detection of C3435T single nucleotide polymorphism. We obtained CC, CT and TT genotype frequencies as 20, 53 and 27%, respectively. According to our results, the C allele in Turkish population (Denizli province, west of Turkey) is found 47% and this data shows similarity with Caucasian (UK and German) populations and significantly lower than African populations (p < 0.001). Our study is the first data on the genotype and allele frequency of the human multidrug resistance (MDR1) Gene C3435T Polymorphism in Denizli Province at regional basis in Turkey. Our results could serve as a basis for large-scale correlation studies on the relevance of C3435T genotype in cancer therapy and other diseases in Turkish population. Investigation of genotype frequencies related with p-glycoprotein substrates should be investigated in large scale at regional bases in Turkish population. The scaled-up data might help either to the use of p-glycoprotein substrates to be used for therapeutic applications and population genetics considering the genotype frequencies possibly occurring throughout the history in Anatolian basin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Taylor JG, Choi EH, Foster CB et al (2001) Using genetic variation to study human disease. Trends Mol Med 7:507–512

    Article  PubMed  CAS  Google Scholar 

  2. Taramelli R, Acquati F (2004) The human genome project and the discovery of genetic determinants of cancer susceptibility. Eur J Cancer 40:2537–2543

    Article  PubMed  CAS  Google Scholar 

  3. Vesell ES (2000) Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 40:930–938

    Article  PubMed  CAS  Google Scholar 

  4. Mancinelli L, Cronin M, Sadee W (2000) Pharmacogenomics: the promise of personalized medicine. AAPS Pharm Sci 2:E4

    Article  CAS  Google Scholar 

  5. Van Ommen GJ (2002) The Human Genome Project and the future of diagnostics, treatment and prevention. J Inherit Metab Dis 25:183–188

    Article  PubMed  Google Scholar 

  6. Marsh S, Kwok P, McLeod HL (2002) SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 20:174–179

    Article  PubMed  CAS  Google Scholar 

  7. Workman P (2003) The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol 52:S45–56

    Article  PubMed  CAS  Google Scholar 

  8. Serretti A, Artioli P (2004) The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 4:233–244

    Article  PubMed  CAS  Google Scholar 

  9. Ueda K, Clark DP, Chen CJ et al (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262:505–508

    PubMed  CAS  Google Scholar 

  10. Chen CJ, Clark D, Ueda K et al (1990) Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 265:506–514

    PubMed  CAS  Google Scholar 

  11. Gottesman MM, Pastan I, Ambudkar V (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610–617

    Article  PubMed  CAS  Google Scholar 

  12. Ambudkar SV, Dey S, Hrycyna CA et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmaco Toxicol 39:361–398

    Article  CAS  Google Scholar 

  13. Schinkel AH, Wagenaar E, Mol CA et al (1996) P-glycoprotein in the blood-brain barrier of mice influences the penetration on pharmacological activity of many drugs. J Clin Invest 97:2517–2524

    Article  PubMed  CAS  Google Scholar 

  14. Hoffmeyer S, Burk O, Von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad 97:3473–3478

    Article  CAS  Google Scholar 

  15. Kim RB, Leake BF, Choo EF et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199

    Article  PubMed  CAS  Google Scholar 

  16. Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174

    Article  PubMed  CAS  Google Scholar 

  17. Molnar J, Szabo D, Mandi Y et al (1998) Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res 18:3033–3038

    PubMed  CAS  Google Scholar 

  18. Haus-Cohen M, Assaraf YG, Binyamin L et al (2004) Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment targeted to an extracellular epitope. Int J Cancer 109:750–758

    Article  PubMed  CAS  Google Scholar 

  19. Niv R, Assaraf YG, Segal D et al (2001) Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein. Int J Cancer 94:864–872

    Article  PubMed  CAS  Google Scholar 

  20. Binyamin L, Assaraf YG, Haus-Cohen M et al (2004) Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody. Int J Cancer 110:882–890

    Article  PubMed  CAS  Google Scholar 

  21. Kioka N, Tsubota J, Kakehi Y et al (1989) P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly 185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 162:224–231

    Article  PubMed  CAS  Google Scholar 

  22. Marzolini C, Paus E, Buclin T et al (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advences and clinical relevance. Clin Pharmacol Ther 75:13–33

    Article  PubMed  CAS  Google Scholar 

  23. Brinkmann U, Roots I, Eichelbaum M (2001) Pharnacogenetics of the human drug-transporter gene MDR1: İmpact of polymorphism on pharmacotherapy. Drug Discov Today 6:835–839

    Article  PubMed  CAS  Google Scholar 

  24. Poncz M, Solowiejczyk D, Harpel B et al (1982) Construction of human gene libraries from small amounts of peripheral blood. Hemoglobin 6:27–36

    PubMed  CAS  Google Scholar 

  25. Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217–221

    Article  PubMed  CAS  Google Scholar 

  26. Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143

    PubMed  CAS  Google Scholar 

  27. Sakaeda T, Nakamura T, Horinouchi M et al (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400–1404

    Article  PubMed  CAS  Google Scholar 

  28. Woodahl EL, Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11–19

    Article  PubMed  CAS  Google Scholar 

  29. Linder MW, Prough RA, Valdes R (1997) Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43:254–266

    PubMed  CAS  Google Scholar 

  30. Jamroziak K, Balcerczak E, Mlynarski W et al (2002) Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol 54:495–500

    PubMed  CAS  Google Scholar 

  31. Ostrovsky O, Nagler A, Korostishevsky M et al (2004) Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther Drug Monit. 26(6):679–684

    Article  PubMed  CAS  Google Scholar 

  32. Bernal ML, Sinues B, Fanlo A et al (2003) Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit 25:107–111

    Article  PubMed  CAS  Google Scholar 

  33. Kerb R, Aynacioglu AS, Brockmoller J et al (2001) The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1:204–210

    PubMed  CAS  Google Scholar 

  34. Kaya P, Gunduz U, Arpaci F et al (2005) Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol. 80(1):26–34

    Article  PubMed  CAS  Google Scholar 

  35. Illmer T, Schuler U, Thiede C et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955–4962

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Pamukkale University Research Foundation with grant number 2002TPF019.

Author information

Authors and Affiliations

  1. Department of Physiology, Medical Faculty, Pamukkale University, 20070, Denizli, Turkey

    Sebahat Turgut & Günfer Turgut

  2. Department of Biophysics, Medical Faculty, Pamukkale University, Denizli, Turkey

    Erol Ömer Atalay

Authors
  1. Sebahat Turgut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Günfer Turgut
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erol Ömer Atalay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebahat Turgut.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turgut, S., Turgut, G. & Atalay, E.Ö. Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. Mol Biol Rep 33, 295–300 (2006). https://doi.org/10.1007/s11033-006-9022-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-006-9022-x

Keywords

Search

Navigation